Lomitapide Shows Promise in Pediatric Homozygous FH

Children and adolescents with homozygous familial hypercholesterolemia could benefit from lomitapide therapy, suggests a trial, although safety concerns and upcoming novel drugs question its place.
Medscape Medical News

source https://www.medscape.com/viewarticle/992523?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost